Ocugen, Inc.
OCGN · NASDAQ
Market closed$1.36$-0.010000 (-0.73%)After hours $1.35 · -0.74%
Key statistics
Previous close$1.37
Open$1.34
Day high$1.38
Day low$1.34
52-week high$2.73
52-week low$0.931000
Market cap460.39M
Volume3.76M
Average volume7.81M
P/E ratio-5.67
Forward P/E—
EPS-0.24
Dividend yield0.00%
Market context
Why it moved
OCGN shares edged lower as the positive momentum from its recently announced binding term sheet with Roots Pharmaceutical to license its OCU400 gene therapy in the Middle East and North Africa faded, while broader investor caution persisted amid high short interest and below-average trading volume.
What is happening
Recent company-specific developments and publisher coverage.
Ocugen, Inc. · July 14, 2026Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaThe Business Journals · July 13, 2026Malvern's Ocugen strikes up to $255M licensing dealStock Titan · July 1, 2026Ocugen’s July retina conference talks include OCU410 phase 2 resultsQuiver Quantitative · June 17, 2026Insider Purchase: Chief Financial Officer of $OCGN Buys 21,000 Shares | OCGN Stock NewsOcugen, Inc. · May 5, 2026Ocugen Provides Business Update with First Quarter 2026 Financial ResultsTradingView · April 22, 2026Ocugen Stock Outlook: Valuation, Cash Runway and Dilution RiskOcugen, Inc. · April 1, 2026Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt DiseaseOcugen, Inc. · March 24, 2026Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Mt Newswire · July 13, 2026Ocugen Signs Term Sheet to License Retinitis Pigmentosa Gene Therapy to Roots Pharmaceutical, Al-Dhow in MENA Region Benzinga · July 13, 2026Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North Africa Benzinga · May 27, 2026Canaccord Genuity Maintains Buy on Ocugen, Lowers Price Target to $11 Mt Newswire · May 14, 2026Ocugen Closes Offering of Senior Notes Due 2034 Benzinga · May 5, 2026Full Transcript: Ocugen Q1 2026 Earnings Call Mt Newswire · May 5, 2026Ocugen Prices $115 Million Convertible Senior Notes Offering Benzinga · May 5, 2026Ocugen Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $1.533M Beat $540.000K Estimate Benzinga · May 4, 2026Ocugen Plans To Commence $115M Senior Notes Offering